Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
arcticnovartis
Sun, 05/31/2026 – 07:19
Read more about Pluvicto™ demonstrated consistent efficacy across key patient subgroups …
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis
Tue, 05/26/2026 – 07:19
Read more about New Novartis data at ERA 2026 advance scientific understanding of kidney disea…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
arcticnovartis
Thu, 05/21/2026 – 07:19
Read more about Novartis advances RLT innovation and reinforces leader…
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
arcticnovartis
Sun, 05/17/2026 – 21:34
Read more about New PSMAddition data show 58% lower risk of PSA progression with Pluv…
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
arcticnovartis
Thu, 05/07/2026 – 15:02
Read more about Novartis breaks ground on Denton, Texas radioligand therapy site; const…
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
arcticnovartis
Thu, 04/30/2026 – 13:04
Read more about Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
…
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis erzielte im ersten Quartal mit prio…
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance rea…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis
Fri, 04/24/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
If…